Conclusions Metabolomic signatures identify three NAFLD subgroups, independent of
histological disease severity. These signatures align with known CVD and genetic risk
factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation
in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.